TransMedics Group (NASDAQ:TMDX) Stock Price Breaks Above 50-Day Moving Average - What's Next?

Key Points

• TransMedics shares rose above their 50-day moving average, trading at $88.24 versus the average of $79.61.
• Third-quarter revenue increased 41.1% year over year to $203.0 million, and adjusted EPS of $0.51 beat analyst estimates. The company raised its 2026 revenue outlook to $764 million–$774 million.
• ENHANCE Part B and DENOVO catalysts have been pushed to early 2027. Analysts’ consensus rating is Hold, with an average price target of $118.60.

TransMedics Group, Inc. (NASDAQ:TMDX - Get Free Report) crossed above its 50 day moving average during trading on Friday. The stock has a 50 day moving average of $79.61 and traded as high as $88.44. TransMedics Group shares last traded at $88.24, with a volume of 3,950,703 shares changing hands.

TransMedics Group News Summary

Here are the key news stories impacting TransMedics Group this week:

• Positive Sentiment: Third-quarter revenue was $203.0 million, up 41.1% year over year and above the roughly $178 million consensus. Adjusted earnings of $0.51 per share also beat estimates of about $0.30, supporting the growth outlook. TransMedics Q3 2026 results
• Positive Sentiment: TransMedics raised its 2026 revenue guidance to $764 million–$774 million, a signal of confidence in continued business growth. Needham also raised its price target from $106 to $110 and reiterated a Buy rating. Revenue guidance and catalyst update Needham recommendations
• Neutral Sentiment: Unusual options activity followed the earnings report, indicating heightened trading interest but not a clear directional signal. Unusual options activity report
• Negative Sentiment: ENHANCE Part B and DENOVO catalysts have shifted to early 2027, delaying potential near-term developments. EPS was also below the year-ago quarter’s $0.66, despite beating analyst estimates. Catalyst timing update

Analyst Ratings Changes

Several research analysts have recently commented on TMDX shares. UBS Group decreased their target price on TransMedics Group from $80.00 to $77.00 and set a "neutral" rating for the company in a research report on Wednesday, August 5th. Wall Street Zen raised shares of TransMedics Group from a "sell" rating to a "hold" rating in a research note on Saturday. Canaccord Genuity Group lifted their price objective on TransMedics Group from $95.00 to $120.00 and gave the stock a "buy" rating in a report on Friday. Zacks Research upgraded shares of TransMedics Group from a "strong sell" rating to a "hold" rating in a report on Monday, November 2nd. Finally, Needham & Company LLC boosted their price objective on shares of TransMedics Group from $106.00 to $110.00 and gave the company a "buy" rating in a report on Friday. Five research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $118.60.

TransMedics Group Trading Up 27.9%

The firm has a market capitalization of $3.05 billion, a P/E ratio of 23.91, a PEG ratio of 0.92 and a beta of 2.14. The business has a 50-day moving average price of $79.61 and a 200-day moving average price of $93.17. The company has a quick ratio of 6.07, a current ratio of 6.62 and a debt-to-equity ratio of 1.62.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last announced its earnings results on Thursday, November 5th. The company reported $0.51 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.30 by $0.21. TransMedics Group had a return on equity of 15.88% and a net margin of 22.69%. The company had revenue of $203.01 million for the quarter, compared to analysts' expectations of $178.06 million. During the same quarter in the previous year, the firm earned $0.66 earnings per share. TransMedics Group's quarterly revenue was up 41.1% on a year-over-year basis. Analysts anticipate that TransMedics Group, Inc. will post 1.46 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director David Weill purchased 1,336 shares of the firm's stock in a transaction that occurred on Friday, September 11th. The shares were acquired at an average price of $81.63 per share, with a total value of $109,057.68. Following the purchase, the director directly owned 16,392 shares in the company, valued at $1,338,078.96. This represents a 8.87% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 6.90% of the company's stock.

Institutional Trading of TransMedics Group

Institutional investors and hedge funds have recently bought and sold shares of the company. Allworth Financial LP lifted its stake in TransMedics Group by 14.9% in the third quarter. Allworth Financial LP now owns 2,895 shares of the company's stock worth $242,000 after acquiring an additional 375 shares during the period. Russell Investments Group Ltd. grew its stake in shares of TransMedics Group by 19.6% in the third quarter. Russell Investments Group Ltd. now owns 19,612 shares of the company's stock worth $1,637,000 after purchasing an additional 3,211 shares in the last quarter. Maryland State Retirement & Pension System lifted its stake in shares of TransMedics Group by 53.8% in the third quarter. Maryland State Retirement & Pension System now owns 7,775 shares of the company's stock valued at $649,000 after buying an additional 2,719 shares during the period. Illinois Municipal Retirement Fund grew its position in shares of TransMedics Group by 7.4% in the 3rd quarter. Illinois Municipal Retirement Fund now owns 17,453 shares of the company's stock valued at $1,456,000 after purchasing an additional 1,207 shares during the period. Finally, Fulcrum Asset Management LLP grew its stake in TransMedics Group by 3,648.0% during the third quarter. Fulcrum Asset Management LLP now owns 5,622 shares of the company's stock worth $473,000 after buying an additional 5,472 shares in the last quarter. 99.67% of the stock is currently owned by institutional investors.

About TransMedics Group

TransMedics Group, Inc is a medical technology company focused on improving organ transplantation through systems that preserve and assess donor organs outside the body. The company's primary platform is the Organ Care System (OCS), a portable, technology-enabled perfusion system designed to maintain organs in a functioning, near-physiologic state during transport and evaluation.

TransMedics offers OCS products for heart, lung and liver transplantation. Its systems are intended to support the use of organs that may not otherwise be suitable for conventional cold-storage methods, potentially expanding the donor pool and providing transplant teams with additional information when evaluating organs for transplantation.

Founded in 1998 and headquartered in Andover, Massachusetts, TransMedics serves transplant centers in the United States and select international markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.